SCHEMBL5908148

SCHEMBL5908148

C=CCOP(=O)(OCCC#N)O[C@H]1C[C@H](n2ccc(NC(=O)c3ccccc3)nc2=O)O[C@@H]1COP(=O)(O)OC(CCC#N)[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N=CN(C)C)nc32)C[C@@H]1O

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.35
▸ P2RY6 Q15077 4/20 0.34
▸ P2RY2 P41231 2/20 0.34
▸ P2RY4 P51582 2/20 0.34
▸ P2RY14 Q15391 2/20 0.34
▸ NT5E P21589 1/20 0.32
▸ F2 P00734 1/20 0.32
▸ TERT O14746 1/20 0.31
▸ TAS1R3 Q7RTX0 1/20 0.31
▸ TAS1R1 Q7RTX1 1/20 0.31
▸ KRAS P01116 1/20 0.31
▸ P2RY1 P47900 1/20 0.30
▸ FUT5 Q11128 1/20 0.30
▸ PLA2G1B P04054 1/20 0.30
▸ ATG4B Q9Y4P1 1/20 0.30
▸ IMPDH2 P12268 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5908163 0.92 TERT (0.35) POLBP2RY6P2RY2P2RY4TERT
SCHEMBL5908154 0.91 POLB (0.38) POLBP2RY6P2RY2P2RY4F2
SCHEMBL5694326 0.86 P2RY6 (0.37) P2RY6P2RY2P2RY4P2RY14NT5E
SCHEMBL5908152 0.86 TAS1R3 (0.34) POLBP2RY6P2RY2P2RY4F2
SCHEMBL5694309 0.84 P2RY6 (0.35) P2RY6P2RY2P2RY4P2RY14NT5E
SCHEMBL5694206 0.79 P2RY12 (0.36) P2RY6P2RY2NT5ETAS1R3TAS1R1
SCHEMBL5694130 0.78 POLB (0.47) POLBP2RY6P2RY2P2RY4P2RY14
SCHEMBL5694266 0.77 P2RY12 (0.35) P2RY6P2RY2TAS1R3TAS1R1KRAS
SCHEMBL5694292 0.76 IMPDH2 (0.39) NT5ETAS1R3TAS1R1KRASFUT5
SCHEMBL5694286 0.74 IMPDH2 (0.36) NT5ETAS1R3TAS1R1KRASFUT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside MITSUI CHEMICALS, INC. (JP) 2006-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside NSUN2, POLR2H, POLB POLB 3/4885P2RY6 4021/4885P2RY2 3700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback